Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/7/2025

Cefuroxime Safety in G6PD Deficiency Patients

Understanding G6PD Deficiency and Medication Safety

  • The severity of G6PD deficiency varies based on genetic variant and ethnic background, with the Mediterranean variant (Gdmed) typically causing more severe reactions than the African variant (GdA-) 2, 1

Medications Contraindicated in G6PD Deficiency

  • Primaquine is contraindicated in G6PD deficiency, as it can cause severe hemolytic anemia in affected patients 2
  • Rasburicase is contraindicated in G6PD deficiency, as it can cause severe hemolytic anemia in affected patients 1
  • Methylthioninium chloride (methylene blue) is contraindicated in G6PD deficiency, as it can cause severe hemolytic anemia in affected patients 1

Clinical Considerations

  • Screening for G6PD deficiency is recommended before starting therapy with oxidant drugs in patients with predisposing racial or ethnic backgrounds (Mediterranean, African, Indian, or Southeast Asian descent) 2, 1
  • When treating G6PD-deficient patients, it's essential to monitor for signs of hemolysis, including jaundice, dark urine, fatigue, and pallor, especially when starting any new medication 1

Practical Recommendations

  • For patients with severe G6PD deficiency and multiple comorbidities, consider monitoring hemoglobin levels after initiating treatment with cefuroxime, though this is not routinely necessary 1